A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus

Archives of Dermatology

Volumn 142, Issue 11, 2006, Pages 1447-1454

  Beissert, Stefan ^a   Werfel, Thomas ^b   Frieling, Uta ^a   Böhm, Markus ^a   Sticherling, Michael ^c,d   Stadler, Rudolf ^e   Zillikens, Detlev ^f,g   Rzany, Berthold ^h,o   Hunzelmann, Nicolas ⁱ   Meurer, Michael ^j   Gollnick, Harald ^k   Ruzicka, Thomas ^l   Pillekamp, Hans ^m   Junghans, Volker ⁿ   Luger, Thomas A ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e KLINIKUM MINDEN   (Germany)

^f UNIVERSITY OF WÜRZBURG   (Germany)

^g UNIVERSITY OF LÜBECK   (Germany)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ UNIVERSITY OF COLOGNE   (Germany)

^j DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^k OTTO VON GUERICKE UNIVERSITY   (Germany)

^l HEINRICH HEINE UNIVERSITY   (Germany)

^m UNIVERSITY OF ULM   (Germany)

ⁿ UNIVERSITY OF GÖTTINGEN   (Germany)

^o CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; DESMOGLEIN 1; DESMOGLEIN 3; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IMMUNOBLOTTING; INFECTION; MALE; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS; AZATHIOPRINE; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; GERMANY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MYCOPHENOLIC ACID; PEMPHIGUS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33751248497     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.142.11.1447     Document Type: Article

References (45)

1. Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell. 1991;67:869-877.
2. Silos SA, Tamai K, Li K, et al. Cloning of the gene for human pemphigus vulgaris antigen (desmoglein 3), a desmosomal cadherin: characterization of the promoter region and identification of a keratinocyte-specific cis-element. J Biol Chem. 1996;271:17504-17511.
3. Hertl M, Schuler G. Bullous autoimmune dermatoses, 1: classification [in German]. Hautarzt. 2002;53:207-221.
4. Hertl M, Schuler G. Bullous autoimmune dermatoses, 2: pathogenesis [in German]. Hautarzt. 2002;53:277-287.
5. Stanley JR. Pemphigus. 5th ed. New York, NY: McGraw-Hill Co; 1999.
6. Anhalt GJ, Labib RS, Voorhees JJ, Beals TF, Diaz LA. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med. 1982;306:1189-1196.
7. Koch PJ, Mahoney MG, Ishikawa H, et al. Targeted disruption of the pemphigus vulgaris antigen (desmoglein 3) gene in mice causes loss of keratinocyte cell adhesion with a phenotype similar to pemphigus vulgaris. J Cell Biol. 1997;137:1091-1102.
8. Stanley JR, Koulu L, Klaus-Kovtun V, Steinberg MS. A monoclonal antibody to the desmosomal glycoprotein desmoglein I binds the same polypeptide as human autoantibodies in pemphigus foliaceus. J Immunol. 1986;136:1227-1230.
9. Hashimoto T, Amagai M, Watanabe K, et al. A case of pemphigus vulgaris showing reactivity with pemphigus antigens (Dsg1 and Dsg3) and desmocollins. J Invest Dermatol. 1995;104:541-544.
10. Dmochowski M, Hashimoto T, Amagai M, et al. The extracellular aminoterminal domain of bovine desmoglein 1 (Dsg1) is recognized only by certain pemphigus foliaceus sera, whereas its intracellular domain is recognized by both pemphigus vulgaris and pemphigus foliaceus sera. J Invest Dermatol. 1994;103:173-177.
11. Amagai M, Koch PJ, Nishikawa T, Stanley JR. Pemphigus vulgaris antigen (desmoglein 3) is localized in the lower epidermis, the site of blister formation in patients. J Invest Dermatol. 1996;106:351-355.
12. Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus: an update. Arch Dermatol. 1996;132:203-212.
13. Stanley JR. Therapy of pemphigus vulgaris. Arch Dermatol. 1999;135:76-78.
14. Aberer W, Wolff-Schreiner EC, Stingl G, Wolff K. Azathioprine in the treatment of pemphigus vulgaris: a long-term follow-up. J Am Acad Dermatol. 1987;16:527-533.
15. Enk AH, Knop J. Treatment of pemphigus vulgaris with mycophenolate mofetil. Lancet. 1997;350:494.
16. Enk AH, Knop J. Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol. 1999;135:54-56.
17. Mimouni D, Anhalt GJ, Cummins DL, Kouba DJ, Thorne JE, Nousari HC. Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil. Arch Dermatol. 2003;139:739-742.
18. Lever WF, Schaumburg-Lever G. Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtained in 63 patients between 1961 and 1975. Arch Dermatol. 1977;113:1236-1241.
19. Werth VP. Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. Arch Dermatol. 1996;132:1435-1439.
20. Roujeau JC. Pulse glucocorticoid therapy: the "big shot" revisited. Arch Dermatol. 1996;132:1499-1502.
21. Rosenberg FR, Sanders S, Nelson CT. Pemphigus: a 20-year review of 107 patients treated with corticosteroids. Arch Dermatol. 1976;112:962-970.
22. Ahmed AR, Hombal S. Use of cyclophosphamide in azathioprine failures in pemphigus. J Am Acad Dermatol. 1987;17:437-442.
23. Appelhans M, Bonsmann G, Orge C, Brocker EB. Dexamethasone- cyclophosphamide pulse therapy in bullous autoimmune dermatoses [in German]. Hautarzt. 1993;44:143-147.
24. Fellner MJ, Katz JM, McCabe JB. Successful use of cyclophosphamide and prednisone for initial treatment of pemphigus vulgaris. Arch Dermatol. 1978;114:889-894.
25. Fleischli ME, Valek RH, Pandya AG. Pulse intravenous cyclophosphamide therapy in pemphigus. Arch Dermatol. 1999;135:57-61.
26. Guibal F, Roujeau JC, Stern RS. Management of acquired bullous skin diseases. N Engl J Med. 1996;334:864-865.
27. Hertl M, Schuler G. Bullous autoimmune dermatoses, 3: diagnosis and therapy [in German]. Hautarzt. 2002;53:352-367.
28. Pandya AG, Sontheimer RD. Treatment of pemphigus vulgaris with pulse intravenous cyclophosphamide. Arch Dermatol. 1992;128:1626-1630.
29. Pasricha JS, Sood VD, Minocha Y. Treatment of pemphigus with cyclophosphamide. Br J Dermatol. 1975;93:573-576.
30. Pasricha JS, Thanzama J, Khan UK. Intermittent high-dose dexamethasonecyclophosphamide therapy for pemphigus. Br J Dermatol. 1988;119:73-77.
31. Neye H. Biochemie der Immunsuppressiva. Arzneimitteltherapie. 1998;16:82-90.
32. Snow JL, Gibson LE. A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients. J Am Acad Dermatol. 1995;32:114-116.
33. Böhm M, Beissert S, Schwarz T, Metze D, Luger T. Bullous pemphigoid treated with mycophenolate mofetil. Lancet. 1997;349:541.
34. Grundmann-Kollmann M, Korting HC, Behrens S, et al. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol. 1999;40:957-960.
35. Lipsky JJ. Mycophenolate mofetil. Lancet. 1996;348:1357-1359.
36. Carter SB, Franklin TJ, Jones DF, et al. Mycophenolic acid: an anti-cancer compound with unusual properties. Nature. 1969;223:848-850.
37. Birkeland SA, Hamilton-Dutoit S. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation. 2003;76:984-988.
38. Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation. 2003;76:1289-1293.
39. Robson R, Cecka JM, Opelz G, Budde M, Sacks S. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant. 2005;5:2954-2960.
40. Sams WM Jr, Jordon RE. Correlation of pemphigoid and pemphigus antibody titres with activity of disease. Br J Dermatol. 1971;84:7-13.
41. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol. 1995;131:193-197.
42. Stolk JN, Boerbooms AM, de Abreu RA, et al. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum. 1998;41:1858-1866.
43. Lapidoth M, David M, Ben-Amitai D, Katzenelson V, Lustig S, Sandbank M. The efficacy of combined treatment with prednisone and cyclosporine in patients with pemphigus: preliminary study. J Am Acad Dermatol. 1994;30:752-757.
44. Pasricha JS, Khaitan BK. Curative treatment for pemphigus. Arch Dermatol. 1996;132:1518-1519.
45. Suzuki S, Kimura T, Ando K, Sawada M, Tamura G. Antitumor activity of mycophenolic acid. J Antibiot (Tokyo). 1969;22:297-302.